Development strategy of KADCYLA (a HER2-targeted antibody and microtubule inhibitor conjugate) for the treatment of patients with inoperable or recurrent HER2-positive metastatic breast cancer
Author:
Affiliation:
1. Chugai Pharmaceutical Co., Ltd. Clinical Research Planning Dept
Publisher
Japan Society of Drug Delivery System
Subject
Pharmaceutical Science
Reference9 articles.
1. 1)Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neuproto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707-12.
2. 2)Cassady JM, Chan KK, Floss HG, Leistner E. Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull (Tokyo). 2004 Jan; 52(1): 1-26.
3. 3)Issell BF, Crooke ST. Maytansine. Cancer Treat Rev. 1978 Dec; 5(4): 199-207.
4. 4)Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010 Mar 15;70(6)2528-37
5. 5)Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther. 2012 May;11(5):1133-42.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Design and Development of Glucocorticoid Receptor Modulators as Immunology Antibody–Drug Conjugate Payloads;Journal of Medicinal Chemistry;2022-02-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3